pipeline-prospector-insert-v1
X

Find FDA Investigational New Drug (IND) Submissions for Oncology

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FS120

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            F-star expects to enroll 70 patients in a Phase 1 dose escalation clinical trial to assess the safety, tolerability and efficacy of FS120 in patients with advanced malignancies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TPST-1495

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            FDA clearance of the IND enables Tempest to initiate its planned Phase 1a/1b clinical trial in patients with advanced solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BDTX-189

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Versant Ventures

            Deal Size: $201.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 29, 2020

            Details:

            Black Diamond was the first company to emerge from Ridgeline, Versant’s Discovery Engine based in the Basel Technology Park.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SRF617

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            U.S.FDA has cleared the IND applications for Surface Oncology's antibody candidates, SRF617 (targeting CD39) and SRF388 (targeting IL-27), Company plans to initiate clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CYNK-001

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            Celularity to initiate first U.S. clinical investigation of allogeneic NK Cell therapy administered Intravenously or intratumorally in patients with glioblastoma Multiforma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TST001

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 20, 2020

            Details:

            TST001 is the first program developed by Transcenta since merger and it took less than 12 months from the identification of preclinical candidate to IND filing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBT-176,Anti-EGFR antibodies

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2020

            Details:

            Bridge Biotherapeutics will start a dose escalation study as the 1st part of phase I/II study in Korea to find the maximum tolerated dose and to observe safety, and anti-tumor efficacy of BBT-176.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NBE-002

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

            Deal Size: $22.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 10, 2020

            Details:

            The funds will enable NBE to advance development of the lead asset NBE-002 through early clinical trials and to further strengthen the development team, management and board of the company.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE1702

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            Acepodia received clearance of its Investigational IND application from U.S FDA to start Phase 1 clinical study of its natural killer cell therapy ACE1702 in patients with HER2-expressing solid tumors.